PPARGC1A and melanoma: On the other hand, PGC-1α overexpression can also lead to different outcomes depending on the cellular context in BRAF driven melanomas: increased PGC-1α expression in primary tumors after BRAF inhibition with vemurafenib causes OxPhos addiction associated with poor patient prognosis (Haq et al., 2013), while it impaired growth rate and invasive abilities in metastatic settings (Luo et al., 2016).